Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
Hodson L, Bhatia L, Scorletti E, Smith DE, Jackson NC, Shojaee-Moradie F, Umpleby M, Calder PC, Byrne CD
European journal of clinical nutrition · 49 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute for Health and Care Research
- Organización sin fines de lucro
- British Heart Foundation
- Organización sin fines de lucro
- Diabetes UK
- Universidad u hospital
- National Institute for Health Research Southampton Biomedical Research Centre
- Gobierno
- National Institute for Health Research (NIHR)
- Subvenciones
- National Institute for Health and Care Research (SOUBRC-1); Diabetes UK (11/0004337); British Heart Foundation (FS/11/18/28633)
Según 5 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2017-03-15 · Eur J Clin Nutr · vol. 71 · número 8 · págs. 973–979
- Editorial
- Springer Nature
- Citado
- 65 citas · más que el 97% de estudios similares · 5.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 34 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY
- Áreas de investigación
- Fatty Acid Research and Health · Liver Disease Diagnosis and Treatment · Metabolomics and Mass Spectrometry Studies
- Palabras clave
- Postprandial, Internal medicine, Docosahexaenoic acid, Endocrinology, Fatty liver, Insulin resistance, Insulin, Lipogenesis, Triglyceride, Polyunsaturated fatty acid, Placebo, Medicine, Biology, Fatty acid, Lipid metabolism, Cholesterol, Biochemistry, Pathology, Disease
- MeSH
- liver, erythrocytes, humans, insulin resistance, 3-hydroxybutyric acid, docosahexaenoic acids, eicosapentaenoic acid, cohort studies, pilot projects, double-blind method, dietary supplements, adult, middle aged, female, male, lipogenesis, lipid metabolism, non-alcoholic fatty liver disease, biomarkers, proof of concept study
9 autores
- Leanne Hodson🇬🇧 · autor de correspondenciaUniversity of Oxford; Oxford Centre for Diabetes, Endocrinology and Metabolism
- Lokpal S. Bhatia
- Eleonora Scorletti🇬🇧University Hospital Southampton NHS Foundation Trust; NIHR Southampton Biomedical Research Centre; University of Southampton
- Debbie E. Smith🇬🇧University Hospital Southampton NHS Foundation Trust; NIHR Southampton Biomedical Research Centre; University of Southampton
- Nicola C. Jackson🇬🇧University of Surrey
- Fariba Shojaee‐Moradie🇬🇧University of Surrey
- Anne Margot Umpleby🇬🇧University of Surrey
- Philip C. Calder🇬🇧University Hospital Southampton NHS Foundation Trust; NIHR Southampton Biomedical Research Centre; University of Southampton
- Christopher D. Byrne🇬🇧University Hospital Southampton NHS Foundation Trust; NIHR Southampton Biomedical Research Centre; University of Southampton
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background/objective
Treatment of subjects with non-alcoholic fatty liver disease (NAFLD) with omega-3 polyunsaturated fatty acids (FAs) suggests high levels of docosahexaenoic acid (DHA) tissue enrichment decrease liver fat content. We assessed whether changes in erythrocyte DHA enrichment (as a surrogate marker of changes in tissue enrichment) were associated with alterations in hepatic de novo lipogenesis (DNL), postprandial FA partitioning and hepatic and peripheral insulin sensitivity in a sub-study of the WELCOME trial (Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD (non-alcoholic fatty liver disease) with OMacor thErapy).
Subjects/methods
Sixteen participants were randomised to 4 g/day EPA+DHA (n=8) or placebo (n=8) for 15-18 months and underwent pre- and post-intervention measurements. Fasting and postprandial hepatic FA metabolism was assessed using metabolic substrates labelled with stable-isotope tracers (2H2O and [U13C]palmitate). Insulin sensitivity was measured by a stepped hyperinsulinaemic-euglycaemic clamp using deuterated glucose. Participants were stratified according to change in DHA erythrocyte enrichment (< or ⩾2% post intervention).
Results
Nine participants were stratified to DHA⩾2% (eight randomised to EPA+DHA and one to placebo) and seven to the DHA13C from dietary fat into plasma 3-hydroxybutyrate (all P<0.05).
Conclusions
The findings from our pilot study indicate that individuals who achieved a change in erythrocyte DHA enrichment ⩾2% show favourable changes in hepatic FA metabolism and insulin sensitivity, which may contribute to decreasing hepatic fat content.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.